Hosted on MSN
Seattle startup Accipiter Bio emerges with $12.7M and big pharma deals for AI-designed proteins
A Seattle biotech startup born from a Nobel laureate’s lab has landed $12.7 million and partnerships with pharmaceutical giants Pfizer and Kite Pharma by using AI to design proteins that mount a multi ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Seattle-based company is ...
SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from ...
An illustration of a protein created by Accipiter Bio that has two active sites, shown in light and darker green, that can simultaneously bind two targets. (Accipiter Bio Image) A Seattle biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results